This is a website for healthcare professionals.
Lupus Nephritis
Uncover what other tests can’t see with AVISE® SLE Monitor, the most advanced autoimmune testing available.
Know more with
AVISE® SLE Monitor
The most advanced assessment available
With a powerful combination of biomarkers that go beyond standard SLE tests, AVISE® SLE Monitor empowers you with the full intel to stay a step ahead of flare ups, regularly monitor disease progression, assess treatment efficacy, and help prevent premature disease advancement and long-term damage.
A more advanced assessment requires a more comprehensive biomarker suite
ES4d is informative even when C3/C4 is unchanged
In a cohort of 124 SLE patients that were followed longitudinally, levels of EC4d fluctuated with disease activity and provided additional information regardless of changes in C3/C4 levels.
22%
Fluctuating C3/C4 Levels
78%
EC4d disease correlation independent of C3/C4 levels in this patient group
Chronic Low or Normal C3/C4 Levels
Marginal R2 =7.9% (p <0.001)
Superior detection of organ involvement
Anti-C1q: Identify the risk of Lupus Nephritis
Anti-C1q is superior to other biomarkers in association with SELENA-SLEDAI values and lupus nephritis. SLE patients with positive levels are 2X more likely to have renal involvement.3
Percent of patients with increased biomarker levels during high disease activity3
Superior detection of changes in disease activity
EC4d: More accurate monitoring
Our proprietary CB-CAPs EC4d test has strong correlation with disease activity and levels decline rapidly with clinical improvement.4
Anti-dsDNA by CIA: Superior accuracy
Chemiluminescence immunoassay (CIA) has expanded dynamic range and demonstrated superior agreement with the Farr assay.1
Superior detection of Lupus Nephritis
EC4d and anti-C1q significantly correlate with decreases in proteinuria observed prospectively—importantly, EC4d had a stronger correlation with uPCR than conventional serum C3/C4.4
Anti-C1q antibodies are significantly associated (OR = 3.2, p < 0.01) with LN independent of demographic and other serological risk factors.1,2
SLE patients who are simultaneously anti-dsDNA, low complement, and anti-C1q positive are most strongly associated (OR = 14.9, p < 0.01) with LN.2
Clinical Utility: AVISE SLE Monitor Test Report
The AVISE SLE Monitor test should be considered any time the condition of a SLE patient is being assessed.
If the patient is also being monitored with AVISE® HCQ, the AVISE SLE Monitor test report will also include an AVISE HCQ test result page.
References:
- Merrill J, et al. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science and Medicine. 2018.
- Orbai, A.-M., Truedsson, L., Sturfelt, G. et al. (2015). Anti-C1q antibodies in systemic lupus erythematosus. Lupus, 24(1): 42–49.
- Akhter E, Burlingame R, Seaman A, et al. Anti-C1Q antibodies have a higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2012.
- Buyon J, et al. Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. Lupus Science and Medicine. 2016.